GOSS
Price
$1.33
Change
+$0.07 (+5.56%)
Updated
Jun 6 closing price
Capitalization
285.26M
64 days until earnings call
RARE
Price
$37.16
Change
+$0.26 (+0.70%)
Updated
Jun 6 closing price
Capitalization
3.49B
52 days until earnings call
Interact to see
Advertisement

GOSS vs RARE

Header iconGOSS vs RARE Comparison
Open Charts GOSS vs RAREBanner chart's image
Gossamer Bio
Price$1.33
Change+$0.07 (+5.56%)
Volume$1.43M
Capitalization285.26M
Ultragenyx Pharmaceutical
Price$37.16
Change+$0.26 (+0.70%)
Volume$930.29K
Capitalization3.49B
GOSS vs RARE Comparison Chart
Loading...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GOSS vs. RARE commentary
Jun 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GOSS is a StrongBuy and RARE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 09, 2025
Stock price -- (GOSS: $1.16 vs. RARE: $34.35)
Brand notoriety: GOSS and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GOSS: 52% vs. RARE: 206%
Market capitalization -- GOSS: $285.26M vs. RARE: $3.49B
GOSS [@Biotechnology] is valued at $285.26M. RARE’s [@Biotechnology] market capitalization is $3.49B. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GOSS’s FA Score shows that 0 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • GOSS’s FA Score: 0 green, 5 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, GOSS is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GOSS’s TA Score shows that 5 TA indicator(s) are bullish while RARE’s TA Score has 4 bullish TA indicator(s).

  • GOSS’s TA Score: 5 bullish, 4 bearish.
  • RARE’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, GOSS is a better buy in the short-term than RARE.

Price Growth

GOSS (@Biotechnology) experienced а +0.87% price change this week, while RARE (@Biotechnology) price change was -2.99% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

GOSS is expected to report earnings on Aug 12, 2025.

RARE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($3.49B) has a higher market cap than GOSS($285M). GOSS YTD gains are higher at: 28.233 vs. RARE (-18.350). GOSS has higher annual earnings (EBITDA): -39.97M vs. RARE (-469M). RARE has more cash in the bank: 610M vs. GOSS (295M). RARE has less debt than GOSS: RARE (40.3M) vs GOSS (203M). RARE has higher revenues than GOSS: RARE (560M) vs GOSS (115M).
GOSSRAREGOSS / RARE
Capitalization285M3.49B8%
EBITDA-39.97M-469M9%
Gain YTD28.233-18.350-154%
P/E RatioN/AN/A-
Revenue115M560M21%
Total Cash295M610M48%
Total Debt203M40.3M504%
FUNDAMENTALS RATINGS
GOSS vs RARE: Fundamental Ratings
GOSS
RARE
OUTLOOK RATING
1..100
214
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
79
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
3981
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GOSS's Valuation (61) in the Pharmaceuticals Major industry is in the same range as RARE (79) in the Biotechnology industry. This means that GOSS’s stock grew similarly to RARE’s over the last 12 months.

GOSS's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as RARE (100) in the Biotechnology industry. This means that GOSS’s stock grew similarly to RARE’s over the last 12 months.

GOSS's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as RARE (99) in the Biotechnology industry. This means that GOSS’s stock grew similarly to RARE’s over the last 12 months.

GOSS's Price Growth Rating (39) in the Pharmaceuticals Major industry is somewhat better than the same rating for RARE (81) in the Biotechnology industry. This means that GOSS’s stock grew somewhat faster than RARE’s over the last 12 months.

GOSS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as RARE (100) in the Biotechnology industry. This means that GOSS’s stock grew similarly to RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GOSSRARE
RSI
ODDS (%)
Bearish Trend 12 days ago
86%
N/A
Stochastic
ODDS (%)
Bearish Trend 12 days ago
85%
Bullish Trend 12 days ago
75%
Momentum
ODDS (%)
Bullish Trend 12 days ago
73%
Bearish Trend 12 days ago
77%
MACD
ODDS (%)
N/A
Bearish Trend 12 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
87%
Bearish Trend 12 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
83%
Bearish Trend 12 days ago
83%
Advances
ODDS (%)
Bullish Trend 20 days ago
84%
Bullish Trend 20 days ago
77%
Declines
ODDS (%)
Bearish Trend 26 days ago
88%
Bearish Trend 12 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
88%
Bullish Trend 12 days ago
72%
Aroon
ODDS (%)
Bullish Trend 12 days ago
83%
Bullish Trend 12 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

GOSS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GOSS has been loosely correlated with VIR. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if GOSS jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GOSS
1D Price
Change %
GOSS100%
+3.57%
VIR - GOSS
41%
Loosely correlated
+2.15%
ALT - GOSS
37%
Loosely correlated
-0.36%
RARE - GOSS
35%
Loosely correlated
-2.08%
IONS - GOSS
35%
Loosely correlated
-2.67%
ARGX - GOSS
35%
Loosely correlated
-0.61%
More

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been loosely correlated with COGT. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if RARE jumps, then COGT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
-2.08%
COGT - RARE
53%
Loosely correlated
N/A
CRNX - RARE
51%
Loosely correlated
+1.39%
DNLI - RARE
51%
Loosely correlated
-1.29%
RVMD - RARE
50%
Loosely correlated
+2.04%
ARWR - RARE
49%
Loosely correlated
+1.24%
More